Device Trial Radar · NCT07195708
Orbera365 Intragastric Balloon System (Abbreviated as'Orbera365')
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
144
Planned (sponsor's estimate)
Start
Jun 3, 2026
Primary completion
Jun 30, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Boston Scientific CorporationPublic (BSX)
- Sponsor type
- Industry
- First posted
- Sep 29, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To demonstrate the safety and efficacy of Orbera365 in obese populations to support the registration of Orbera365.
Conditions
- Weight Loss
Interventions
Treatment groupDevice
The treatment group was the group with the placement of Orbera 365 plus lifestyle management
Primary outcomes
What the sponsor says the trial is designed to measure.
- %TBWL (Defined as the percentage of total body weight loss)Time frame: At 12 months after the intervention
- The response rate at the 12th month after the interventionTime frame: At 12 months after the intervention
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Changhai Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.